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Background:!The PREDICt-RM study found that Remote Patient Monitoring (RPM) was used 
by less than half of eligible patients with implantable cardioverter-defibrillators (ICDs) between 
2006 and 2010 despite guideline recommendations. We investigated whether the addition of new 
Current Procedural Terminology (CPT) codes for RPM in January 2009 had impact on 
utilization of RPM technology and whether the impact varied by race or geographic region.  
Methods: We used multivariable logistic regression to determine whether subjects in the 
PREDICt-RM study cohort receiving an ICD post-coding change were more likely to enroll in an 
RPM program or activate RPM (transmit RPM data) within 180 days of implant, versus those 
implanted pre-coding change. Rate differences between the post and pre-coding change periods 
were calculated overall and for racial and regional subgroups.  
Results: Subjects implanted after the 2009 coding change were less likely to enroll (OR 0.76) 
and more likely to activate (OR 1.27). Enrollment rates in the Post period were significantly 
lower than the Pre period in most regions and among all races. Activation rates were higher in 
most regions, but only among white subjects. !
Conclusion: The 2009 CPT coding change was not associated with an appreciable rise in RPM 
utilization, and minorities continue to underutilize the technology to a greater extent than white 
patients. There is a need for the professional community to standardize the implementation of 
RPM technology in routine practice, and further studies should examine patient and provider 
motivations for utilizing RPM.  
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Implantable cardioverter-defibrillator (ICD) therapy is indicated for patients at risk of 
sudden cardiac death due to ventricular arrhythmias1. These devices are implanted in patients to 
monitor cardiac rhythm and deliver antiarrhythmic therapies if potentially lethal arrhythmias are 
detected. Current practice guidelines recommend routine patient follow-up visits every 3 to 6 
months after ICD implant in order to both evaluate system function and lead integrity, download 
telemetry, and make programming changes if necessary2. The longer a patient has had an ICD, 
the greater the risk for device malfunction, poor signal-to-noise ratios, under-detection of 
significant clinical events, and inappropriate shock delivery3. 
As indications for ICD therapy have expanded over the last decade, there has been a 
concomitant increase in the number of implants and the rate of in-person follow up1,4 
Traditionally, follow-up evaluations occur during regularly scheduled office visits, imposing 
significant burden on patients, physicians and health care facilities5. Remote patient monitoring 
(RPM) has emerged as an alternative mode of follow-up that may supplant office visits. RPM 
systems allow patients to transmit ICD data to their health care providers through a 
communicator device installed in the home6. Compared to traditional monitoring, this model has 
been found to enhance the discovery of clinically significant events, reduce hospitalizations, and 
expedite clinical decision-making7-10 without adding substantial burden to clinicians’ workload11. 
Furthermore, studies suggest that RPM may reduce the risk of mortality and reduces health care 
costs compared with in-office follow up visits12-14. 
Successful use of RPM consists of two steps. Providers must first enroll patients into an 
RPM program, and patients must then activate RPM by making an initial data transmission from 
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home. These actions must both occur to begin RPM, and potential barriers to utilization exist at 
both stages.  
On January 1st, 2009, new current procedural technology (CPT) codes for remote 
monitoring of ICDs went into effect. CPT codes are developed by the American Medical 
Association (AMA) and provide a systematic way of describing medical services for 
documentation and billing purposes.  The addition of RPM codes for ICDs in January 2009 was 
a signal of RPM’s acceptance as part of professional practice, as new CPT codes typically 
emerge as a result of the professional community demonstrating support and need for their 
inclusion15. However, the lack of a uniform process for billing remote device interrogation before 
the January 2009 coding change5 coding change could conceivably have been a barrier to uptake 
of RPM. Conversely, standardization of billing for RPM may have facilitated its uptake.  
The recent Patient RElated Determinants of ICD Remote Monitoring (PREDICt-RM) 
study found that less than half of patients implanted with Boston Scientific Corporation (BSC) 
ICDs between 2006 and 2010 utilized RPM technology16 Investigators also identified lower rates 
of utilization in coastal regions of the U.S. and among racial minorities. In the present 
investigation, we build on the findings of the PREDICt-RM study by examining whether the 
January 2009 CPT coding change had a measurable impact on enrollment and activation rates in 
the PREDICt-RM cohort. Secondarily, we explore race and region-based variation in the 
differences in enrollment and activation rates between the period before the coding change and 
the period after. Given increasing indications for ICD therapy and the increasing acceptance of 
RPM among practitioners, we expect enrollment and activation rates to increase following the 
advent of new CPT codes.    
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Methods 
Data sources and cohort derivation 
 Derivation of the study database and study cohort are described in detail in the methods 
section of the parent PREDICt-RM study16.Briefly, a de-identified, limited data set from the BSC 
ALTITUDE database was indirectly linked to a limited data set from the National 
Cardiovascular Data Registry (NCDR®) ICD Registry™ based on Hospital Medicare provider 
number (MPN), patient age, patient gender, and date of implantation. The ALTITUDE database, 
which encompasses patients implanted with RPM-capable ICDs manufactured by BSC, includes 
data on ICD implantation date, device model number, patient age, gender, and zip code, dates of 
enrollment into BSC’s LATITUDE RPM program and dates of device data transmission.  
Patients who could not be linked between the ALTITUDE and ICD Registry data sets 
were excluded. The linked cohort was then subjected to the following exclusion criteria: patients 
who had received a cardiac transplant or surgical epicardial lead, patients implanted at hospitals 
not reporting all of their ICDs, patients with unknown vital status, patients who died during the 
implanting hospital stay, and patients with invalid enrollment and activation dates. The final 
cohort consists of 39,158 subjects who underwent ICD implantation between January 2006 and 
March 2010.  
The study cohort was divided into two subcohorts according to the date of ICD 
implantation. The “Pre” subcohort consisted of subjects who underwent ICD implantation 
between January 2006 and December 2008, prior to the January 1st, 2009 CPT coding change, 
The “Post” subcohort consisted of subjects who received ICDs between January 2009 and March 
2010, after the coding change. 
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Outcomes 
As defined in the PREDICt-RM study, the primary outcomes of interest were enrollment 
and activation of RPM. Subjects were classified as “enrolled” if enrollment in the LATITUDE 
RPM program occurred within 180 days of device implantation. Subjects who were not enrolled 
by 180 days post-implant were considered “not enrolled.” Similarly, out of those enrolled, 
subjects were classified as “active” if they first transmitted data from home within 180 days of 
implant. Subjects not activated by 180 days post-implant were considered “inactive.” The 180-
day timeframe captures the majority of enrollments and activations, which typically occur within 
weeks after ICD implantation. Enrollments and activations taking place after the 180-day period 
are likely related to interim changes in health status, and therefore may not reflect the context of 
routine RPM use.  
As enrollment is a pre-condition for activation, activated subjects are a subset of enrolled 
subjects. Subjects who enrolled in RPM but never transmitted data were considered enrolled but 
inactive. All subjects in the study database were categorized based on enrollment and activation 
status.  
Statistical Analysis  
Demographic, clinical, physician, hospital and regional characteristics were compared 
between the Pre and Post subcohorts using Chi-square tests for categorical variables and 
student’s t-tests for continuous variables, using a significance level of α=0.05. For categorical 
variables with a missing rate less than or equal to 5%, missing values were assumed to represent 
the most common category. A “missing” category was added for categorical variables with a 
missing rate greater than 5%. For continuous variables, the median value for the overall cohort 
was used to impute missing values. Rates of enrollment and activation were calculated as follows. 
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Enrollment rate was defined as the percentage of subjects who enrolled in RPM within 180 days 
of implant, out of those who received ICDs. Activation rate was defined as the percentage of 
subjects who activated RPM within 180 days of implant, out of enrolled subjects.   
Absolute differences between Pre and Post enrollment and activation rates were 
calculated overall and for racial and regional subgroups. Rate differences were tested for 
significance using Chi-square tests for equality of proportions (α=0.05). Breslow-Day tests for 
heterogeneity were conducted to determine whether the association of time period with 
enrollment and activation varied based on race or region (α=0.05). Breslow-Day tests were 
Tarone-adjusted to account for low frequencies in minority racial groups and less populated 
geographic regions. 
Multivariable logistic regression analyses were performed to determine whether the time 
period (Pre or Post coding change) was an independent predictor of enrollment and of activation. 
Covariates were selected from the models for RPM enrollment and activation developed in the 
PREDICt-RM Phase I study. To develop these models, Phase I investigators performed 
multivariable logistic regression with stepwise selection (p-value for variable entry = 0.1, p-value 
for variable retention = 0.05), followed by a bootstrapping procedure with 1000 iterations. The 
final enrollment and activation models included variables that were selected in over 70% of the 
iterations. In the present investigation, we included the same covariates identified in these prior 
analyses, and included an indicator for Pre or Post status to each baseline model and assessed for 
significance. The baseline enrollment model included 21 variables, and the baseline activation 
model included 17 variables. Likelihood ratios were compared between the baseline models and 
the new models to determine whether addition of the Pre Post indicator improved model fit. C-
statistics were also compared to assess whether the indicator improved model discrimination. 
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SAS version 9.3 (SAS Institute, Cary, NC) was used for all analyses. Tables and figures were 
created in SAS 9.3 and Microsoft Excel version 12.3.4 (Microsoft Corporation, Redmond, WA).  
Results 
Subject Characteristics and Overall Trends ! The quarterly volume of RPM-capable Boston Scientific ICD implants increased over the 
study period, suggesting rising acceptance of RPM-capable technology into routine practice 
(Figure 1). Although the Post-CPT coding change period was 9 months shorter than the Pre 
period (15 months vs. 24 months), implant volumes were nearly equal in the two periods. Of the 
39,158 subjects in the overall cohort, 19,669 received ICD implants in the Pre period, and 19,489 
in the Post period (Table 1). Post subjects were significantly younger than Pre subjects (65.6 
years vs. 67.9 years, p<0.0001) and more likely to be non-white (p<0.0001). Both groups were 
predominantly male, and gender distributions were not significantly different (p=0.5689). Post 
subjects were slightly more likely to have undergone implantation in the New England, Central 
and Mountain regions (p=0.0026).  
 Enrollment rates appear generally higher in the Pre period than the Post period (Figure 
2a). Activation rates remained above 60% over the entire period and did not appear significantly 
different in the Post period than the Pre period (Figure 2b).  
Enrollment and Activation Rates  
Table 2 contains enrollment and activation rates stratified by race and region, as well as 
the absolute rate differences between the Pre and Post periods. Overall, enrollment in the post 
period was 7.5% lower than in the Pre period (95% CI -8.5%, -7.5%; p<0.0001) while activation 
was 3.4% higher (95% CI 2.5%, 4.5%; p<0.0001). Post enrollment rates were significantly lower 
! 11!
than Pre enrollment rates in all U.S. regions except for New England, and Other, where there was 
no significant difference between enrollment rates in the two periods, The drop in enrollment 
was most pronounced in the Atlantic and Pacific regions (-10.2% and -10.7%, respectively) Post 
activation rates were significantly higher in the Atlantic, Central, Pacific and Other regions, but 
did not significantly change in New England or the Mountain region. The Other region saw the 
greatest rise in enrollment in the Post period (7.0%, 95% CI 1.42%, 12.6%). Among all racial 
subgroups, enrollment rates were significantly lower in the Post period. Only the white subgroup 
had a significantly higher Post activation rate. In non-white racial subgroups, Post activation 
rates were not significantly different than Pre rates.  
Within regions, enrollment rate differences in racial subgroups were similar to the 
difference observed in the region overall: enrollment rates decreased across all racial groups in 
the Atlantic and Pacific, and for all except Other races in the Central region. The significantly 
higher overall Post activation rates observed in the Atlantic, Central, Pacific and Other regions 
were mirrored in the white subgroup only. Minority racial subgroups within those regions did not 
experience any changes in activation rates. In general, enrollment rates did not rise in any racial 
or regional subgroups, and only white patients experienced a modest rise in activation rates 
(4.0%, 95% CI 2.9%, 5.2%). Race-based variation in Pre vs. Post differences in activation rates 
demonstrate that minority patients continue to underutilize RPM to a greater extent than white 
patients following the coding change.  
The Breslow-Day test revealed heterogeneity in the effect of time period on enrollment 
by race (p=0.0055) and by region (p<0.0001). Hispanic and Other subjects had greater decreases 
in enrollment (-11.6%, -12.7%, respectively) than white and black subjects (-6.0%, -9.5%, 
respectively). Enrollment decreased more in the Atlantic, Mountain and Pacific regions (-10.2%, 
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-9.1%, -10.7%, respectively) than in the Central and Other regions (-5.8%, -1.8%, respectively). 
and there was also heterogeneity by race within the Pacific region (p=0.0006): black, Hispanic, 
and Other subjects experienced sharper drops in enrollment rates than white subjects (- 21.0%, -
20.6%, and -19.6%, respectively, vs. -5.5%). The effect of time period on activation was 
heterogeneous by race overall and in the Central region (p=0.0425, p=0.0017, respectively) 
Risk-Adjusted Analyses 
 Post subjects were significantly less likely to enroll in RPM than Pre subjects in risk-
adjusted analyses (OR 0.76, 95% CI 0.73, 0.80; Figure 3). The likelihood ratio test indicated that 
the addition of the time period variable to the enrollment model significantly improved fit 
(p<0.0001). Model discrimination also improved slightly (c=0.671 vs. c=0.668 for the baseline 
model).  
 Post subjects were significantly more likely to activate RPM than Pre subjects (OR 1.27, 
95% CI 1.19, 1.36; Figure 4). The likelihood ratio test indicated that model fit was significantly 
better with the addition of the time period variable (p<0.0001). There was a modest increase in 
discriminatory power (c=0.622 vs. c=0.618 for the baseline model).  
Discussion 
Our findings demonstrate that even though there was an overall increase in the number if 
RPM-capable ICD implants over the 2006-2010 period, there was a decrease in RPM enrollment 
rates after the 2009 CPT coding change. Despite the decrease in enrollment, the proportion of 
subjects that activated RPM out of those who enrolled increased. However, the increase in 
activation was not experienced by minority subgroups, and enrollment decreases in those groups 
were more pronounced than for the white subgroup. The observed drop in RPM enrollment rates 
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following the January 2009 coding change is unexpected, particularly against a backdrop of the 
professional community’s increasing support for the use of RPM17,18. Although the overall 
increase in activation represents a favorable trend, it is not enough to offset the impact of 
decreased enrollment. The observed racial disparities in RPM utilization also merit further study. 
It is possible that physician bias plays a role in underutilization among minorities, whereby 
minority patients are less likely to be encouraged to enroll in RPM programs.  
 The Phase I parent study concluded that enrollment was primarily dependent on provider 
and institutional factors, while activation relied more on patient-related factors. In the latest 
investigation, the discrepancy between increased likelihood of enrollment and decreased 
likelihood of activation after the coding change further highlights the fact that enrollment and 
activation are two separate processes with distinct determinants. These findings raise questions 
about the patient and physician factors contributing to the utilization of RPM technology. 
Providers and patients may jointly determine that RPM is less appropriate than in-office follow 
up for a variety of reasons. Providers may prefer in-office follow-up for certain patients out of 
concern for lack of compliance with data transmission procedures. Providers that have 
successfully cared for ICD patients in person for years may be hesitant to adopt RPM. Similarly, 
patients may feel more comfortable seeing their providers in person. These factors may influence 
the decision not to enroll in RPM, but they do not fully explain why some patients enroll but 
never activate.  
 Although RPM has evolved and matured over the past decade, it is still a relatively new 
technology, and guidelines for its usage are not yet prescriptive19. Despite the advent of a unified 
billing scheme for RPM, the parameters for the application of RPM in routine practice have yet 
to be standardized. Ideally, each provider and institution should have protocols in place for 
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managing their remotely monitored ICD patients that address such details as the division of 
administrative and clinical responsibilities among members of the remote monitoring care team, 
procedures for responding to detected clinical events, and handling of confidential remote 
monitoring data. It remains unclear what the best practices are in each of these domains. In 
addition, the nature of providers’ and institutions’ legal liability surrounding an RPM-detected 
event is poorly defined. For instance, it is unclear whether failure to immediately respond to an 
event alert constitutes negligence19. The professional community will need to clarify the 
logistical, ethical, and legal framework of RPM in anticipation of its more widespread adoption. 
In the meantime, the absence of an established framework for implementing RPM in a clinical 
context may pose a significant barrier to its uptake by providers and institutions.  
Limitations 
The present study did not take into account in-person office visits, so it is unclear whether 
those who did not enroll in or activate RPM elected to use the traditional mode of follow-up, or 
whether they neglected to follow up altogether. Secondly, the PREDICt-RM database included 
only RPM-capable ICDs from Boston Scientific Corporation. Non-RPM capable devices, and 
devices from other manufacturers were not taken into account. Furthermore, all the devices in the 
database were landline-dependent, which may have posed a barrier to patients of lower 
socioeconomic status who are less likely to have landline access6,16. Wireless RPM systems that 
can transmit data over cellular networks are becoming increasingly available, reducing the 
reliance on landlines. Thus, the findings of this study may not be generalizable to the utilization 
of other types of RPM systems. Further, the racial and regional subgroups in which Post rates 
were not significantly different than Pre rates (Table 2) had the fewest subjects, implying 
insufficient statistical power to detect a difference rather than a true lack thereof.   
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This analysis was also unable to capture physician and patient rationales for not utilizing 
RPM. Future qualitative studies examining patients’ and providers’ decision-making processes 
surrounding enrollment in and activation of RPM are warranted, as are prospective studies of 
whether patients in the PREDICt-RM cohort who utilized RPM experience better clinical 
outcomes. 
Conclusion 
 The 2009 CPT coding change that incorporated uniform codes for remote patient 
monitoring of ICDs is not associated with an appreciable rise in RPM utilization. Unexpectedly, 
RPM enrollment rates were significantly lower after the coding change, whereas activation rates 
were higher, although the increase was limited to white patients. Enrollment rates decreased 
most sharply in the Atlantic, Mountain and Pacific regions and among racial and ethnic 
minorities. A qualitative investigation of patients’ and providers’ respective motivations for 
utilizing RPM technology would help elucidate the modifiable provider-related, institution-
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